4 ms·

I have not heard of anti-ICOS (Inducible costimulatory receptor) before. Seems specific to TME. KY1044 with mouse models (different authors): https://aacrjour

I have not heard of anti-ICOS (Inducible costimulatory receptor) before. Seems specific to TME. KY1044 with mouse models (different authors): https://aacrjournals.org/cancerimmunolres/article/8/12/1568/469583/An-Antibody-Targeting-ICOS-Increases-Intratumoral https://aacrjournals.org/cancerimmunolres/article/8/12/1568/... KY1044 I think is Kymab in Cambridge: https://www.kymab.com/pipeline/ky1044/ https://www.kymab.com/pipeline/ky1044/

ma2t 4y ago
Yes, Sanofi licensed from Kymab. There are a few groups targeting ICOS/ICOSL to modulate immune response to tumor (either alone or in combo with PD-1, CTLA-4, etc approaches previously mentioned on HN). Here's one reasonably recent backgrounder on rationale: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/ Still not clear that KY1044 really is the "experimental drug" mentioned in the linked BBC article, since as others have noted the article is pretty thin on detail.